VioXX is a drug that was recently announced by Pfizer.
It is a generic version of Advil, the brand name of a drug used for heartburn.
Vioxx has been under development for several years now.
Pfizer’s company marketing chief Chris Kallenberg, who previously worked at AstraZeneca, said at the time that the company “is building an industry leader in personalized medicine and is proud to partner with Virginias to offer a unique solution for the needs of patients and physicians”.
The company has made headlines before for their focus on reducing the number of drugs a patient has to take.
Their approach is one of the most widely criticized pharmaceuticals of the 21st century.
Kallenberg said that the new ad campaign is aimed at educating the public on the benefits of Vioxtro, and the pharmaceutical industry in general.
“I think the campaign will have an impact on how people perceive VioXTro as a medicine,” Kallenburg said.
“The key is educating people about the benefits, and also the risks, of taking VioX.”
This will be the first ad campaign to feature a Virginias pharmaceutical in over five years, according to the company.
“VioXTra is the brand new medicine of the year and the brand will be synonymous with Virginia,” the company said in a statement.
“Our brand and product have a rich history of delivering world class health care solutions that will enable Virginias customers to reach their full potential.
We are confident that the Vioxox ads will continue to drive sales of VIOX and help us reach our goal of growing our business.”
Virginias CEO, James Karp, is an ardent supporter of the drug.
In a press release, Karp said the new ads will help inform consumers about the “new and exciting product”.
“The new Vioxpix ad campaign will highlight the promise of Viosoftrx, which is an innovative and revolutionary new treatment for severe, debilitating and terminal diseases,” Karp added.
“The new campaign will also highlight Virginias leadership in this area of medicine.”
The campaign is expected to be launched this week.